delusions and hallucinations are schizophrenic symptoms that have limited evidence showing decrease by drugs that selectively block the d2 dopamine receptor.
delusions and hallucinations are schizophrenic symptoms that have limited evidence showing decrease by drugs that selectively block the d2 dopamine receptor.
what schizophrenic symptoms have limited evidence showing decrease by drugs that selectively block the d2 dopamine receptor?
delusions and hallucinations
because the nature of acute schizophrenia is similar to depression, it is difficult to differentiate normal levels of depression in patients with schizophrenia from depressive levels in post-schizophrenic depression. "prominent subjectively low mood, suggesting depression, and prominent blunting of affect, suggesting negative symptoms, are the two features which are most helpful in differentiating [schizophrenia and depression]." a number of researchers believe that depression is actually a symptom of schizophrenia that has been hidden by the psychosis. however, symptoms usually arise after the first psychotic episodes if they will arise at all. officially, diagnosing post-schizophrenia depression in a patient requires for the patient to be experiencing a depressive episode of either short or long term following the overcoming of schizophrenia. the patient must still demonstrate some schizophrenic symptoms but those symptoms must no longer be the focus of the illness. typically, the depressive symptoms are not severe enough to be classified as a severe depressive episode. formally, diagnosis entails the patient having had schizophrenia within the past year, a number of schizophrenic symptoms, and depression being present for two weeks or more. mild schizophrenic signs may be withdrawing socially, agitation or hostility, and irregular sleep such as in the case of insomnia and hypersomnia.
post-schizophrenic depression
dopamine receptor d2









































dopamine receptor d, also known as d2r, is a protein that, in humans, is encoded by the "drd2" gene. after work from paul greengard's lab had suggested that dopamine receptors were the site of action of antipsychotic drugs, several groups (including those of solomon snyder and philip seeman) used a radiolabeled antipsychotic drug to identify what is now known as the dopamine d receptor. the dopamine d receptor is the main receptor for most antipsychotic drugs. the structure of drd2 in complex with the atypical antipsychotic risperidone has been determined.









































section::::function.
dopamine receptor d2